Collectively, these findings suggest that MZT2A is involved in immune cell infiltration and the tumor microenvironment, may promote KIRC progression, and is overexpressed in cases with poor outcomes, supporting its potential as a diagnostic and prognostic biomarker. The gene discussed is MZT2A; the disease is neoplasm.